162 related articles for article (PubMed ID: 2137979)
1. Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy.
Barbieri RL
Am J Obstet Gynecol; 1990 Feb; 162(2):593-5. PubMed ID: 2137979
[TBL] [Abstract][Full Text] [Related]
2. Treatment of leiomyomata uteri with short-term leuprolide followed by leuprolide plus estrogen-progestin hormone replacement therapy for 2 years: a pilot study.
Friedman AJ
Fertil Steril; 1989 Mar; 51(3):526-8. PubMed ID: 2537769
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonists: strategies for managing the hypoestrogenic effects of therapy.
Judd HL
Am J Obstet Gynecol; 1992 Feb; 166(2):752-6. PubMed ID: 1531578
[TBL] [Abstract][Full Text] [Related]
4. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
5. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist plus medroxyprogesterone acetate.
Cedars MI; Lu JK; Meldrum DR; Judd HL
Obstet Gynecol; 1990 Apr; 75(4):641-5. PubMed ID: 2138265
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
7. Analysis of Adherence, Persistence, and Surgery Among Endometriosis Patients Treated with Leuprolide Acetate Plus Norethindrone Acetate Add-Back Therapy.
Soliman AM; Bonafede M; Farr AM; Castelli-Haley J; Winkel C
J Manag Care Spec Pharm; 2016 May; 22(5):573-87. PubMed ID: 27123918
[TBL] [Abstract][Full Text] [Related]
8. Minimising menopausal side effects whilst treating endometriosis and fibroids.
Simpson PD; McLaren JS; Rymer J; Morris EP
Post Reprod Health; 2015 Mar; 21(1):16-23. PubMed ID: 25802141
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri.
Friedman AJ; Barbieri RL; Doubilet PM; Fine C; Schiff I
Fertil Steril; 1988 Mar; 49(3):404-9. PubMed ID: 2963759
[TBL] [Abstract][Full Text] [Related]
10. [Gonadotropin-releasing hormone analogs].
Krysiak R; Okopień B; Herman ZS
Pol Merkur Lekarski; 2005 May; 18(107):585-9. PubMed ID: 16161962
[TBL] [Abstract][Full Text] [Related]
11. The value of gonadotropin-releasing hormone-agonists together with other drugs for medical treatment and prevention.
Schindler AE
Gynecol Endocrinol; 2009 Dec; 25(12):765-7. PubMed ID: 19905992
[No Abstract] [Full Text] [Related]
12. [Estrogen-progesterone "add-back" for long-term GNRH analogue therapy].
Levy T; Ben-Rafael Z
Harefuah; 1995 Jun; 128(12):789-92. PubMed ID: 7557691
[No Abstract] [Full Text] [Related]
13. The Effects of Gonadotropin-Releasing Hormone Agonist Combined with Add-Back Therapy on Quality of Life for Adolescents with Endometriosis: A Randomized Controlled Trial.
Sadler Gallagher J; Feldman HA; Stokes NA; Laufer MR; Hornstein MD; Gordon CM; DiVasta AD
J Pediatr Adolesc Gynecol; 2017 Apr; 30(2):215-222. PubMed ID: 26927501
[TBL] [Abstract][Full Text] [Related]
14. Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial.
Surrey ES; Judd HL
J Clin Endocrinol Metab; 1992 Aug; 75(2):558-63. PubMed ID: 1386374
[TBL] [Abstract][Full Text] [Related]
15. Treatment of uterine fibroids: current findings with gonadotropin-releasing hormone agonists.
Adamson GD
Am J Obstet Gynecol; 1992 Feb; 166(2):746-51. PubMed ID: 1531577
[TBL] [Abstract][Full Text] [Related]
16. [Conservative surgery combined with depot medroxyprogesterone acetate in treatment of moderate or severe endometriosis].
Zhou J; Lei ZW; Lü JQ; Sun J; Xu XW
Zhonghua Fu Chan Ke Za Zhi; 2005 Jan; 40(1):5-8. PubMed ID: 15774083
[TBL] [Abstract][Full Text] [Related]
17. Add-back therapy use and its impact on LA persistence in patients with endometriosis.
Fuldeore MJ; Marx SE; Chwalisz K; Smeeding JE; Brook RA
Curr Med Res Opin; 2010 Mar; 26(3):729-36. PubMed ID: 20092387
[TBL] [Abstract][Full Text] [Related]
18. Serum CA 125 concentrations in women with endometriosis or uterine fibroids treated with gonadotrophin-releasing hormone agonist analogues.
van der Spuy ZM; Wood M; Fieggen G; Hendricks MS
S Afr Med J; 1993 Jul; 83(7):510-3. PubMed ID: 8211493
[TBL] [Abstract][Full Text] [Related]
19. Combined oestrogen-progestin treatment of vaginal haemorrhage following gonadotrophin-releasing hormone agonist therapy of uterine myomas.
Friedman AJ
Hum Reprod; 1993 Apr; 8(4):540-2. PubMed ID: 8501181
[TBL] [Abstract][Full Text] [Related]
20. Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years.
Friedman AJ; Daly M; Juneau-Norcross M; Gleason R; Rein MS; LeBoff M
Hum Reprod; 1994 Sep; 9(9):1618-25. PubMed ID: 7836510
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
